1. Xiao, Benli, Ge, Yuzhen, Zhao, Rui, Chao, Zheng, Zuo, Shi. 2023. NAP1L5 facilitates pancreatic ductal adenocarcinoma progression via TRIM29-mediated ubiquitination of PHLPP1. In Biochemical pharmacology, 217, 115811. doi:10.1016/j.bcp.2023.115811. https://pubmed.ncbi.nlm.nih.gov/37717692/
2. Zhao, Rui, Ge, Yuzhen, Gong, Yongjun, Xiao, Benli, Zuo, Shi. 2022. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway. In Aging, 14, 9000-9019. doi:10.18632/aging.204377. https://pubmed.ncbi.nlm.nih.gov/36374212/
3. Guo, Ningning, Zheng, Di, Sun, Jiaxin, Tong, Jingjing, Wang, Zhihua. 2021. NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During Cardiomyocyte Hypertrophy. In Frontiers in cardiovascular medicine, 8, 791501. doi:10.3389/fcvm.2021.791501. https://pubmed.ncbi.nlm.nih.gov/34977198/
4. Wu, Huan, Luo, Hang, Wang, Meng, Du, YuQing, Li, Jiajia. 2024. NAP1L5 promotes epithelial-mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia. In Leukemia research, 148, 107623. doi:10.1016/j.leukres.2024.107623. https://pubmed.ncbi.nlm.nih.gov/39579659/
智鼠故事 
